Abstracts tagged "Polymyalgia Rheumatica (PMR)"

Abstract Number: 0743 • ACR Convergence 2024
Higher Baseline FDG Musculoskeletal Uptake at PET/CT Is Associated with a Higher Remission Rate in Polymyalgia Rheumatica: A Retrospective 3-year Observational Study
Elvis Hysa¹, Dario Camellino², Cristina Bernini³, Paolo Vittoriano Clini⁴, Matteo Bauckneht⁵, silvia Morbelli⁶, Gianmario Sambuceti⁵, Emanuele Gotelli⁷, Alberto Sulli⁸, Maurizio Cutolo⁷ and Marco Amedeo Cimmino¹, ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ²Division of Rheumatology, Local Health Trust 3, Genoa, Italy, ³Emergency Medicine Department, San Martino Polyclinic Hospital, Genoa, Italy,, Genoa, Italy, ⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁵Nuclear Medicine Unit and Department of Health Sciences, University of Genova, Genoa, Italy, Genoa, Italy, ⁶University of Torino, Torino, Italy, ⁷Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, ⁸Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Genova, Italy
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related inflammatory diseases characterized by increased musculoskeletal and vascular uptakes of 18-Fluorodeoxyglucose (18F-FDG) at positron…
Abstract Number: 1622 • ACR Convergence 2024
18F-FDG PET/CT in LVV During Active and Inactive Disease Phases Is Associated with the Metabolic Profile, but Not with Macrophage-related Cytokines: Results of an Integrated Analysis
Dimitrios Anastasios Palamidas¹, Georgios Kalykakis², Dimitra Benaki³, Loukas chatzis¹, Ourania Argyropoulou⁴, Panagiota Palla⁴, Antonia Kollia⁵, Pavlos Kafouris⁵, Marinos Metaxas⁵, Andreas Goules⁶, Emmanuel Mikros⁷, Konstantinos Kambas⁸, Constantinos Anagnostopoulos⁵ and Athanasios Tzioufas⁹, ¹Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ²Department of Informatics, Ionian University, Kerkyra, Greece, Athens, Greece, ³Department of Pharmaceutical Chemistry, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁴Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, ⁵PET-CT Department & Preclinical Imaging Unit, Center for Experimental Surgery, Clinical & Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece., Athens, Greece, ⁶GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, ⁷Department of Pharmaceutical Chemistry, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, ⁸Laboratory of Molecular Genetics, Department of Immunology, Hellenic Pasteur Institute, Athens, Greece., Athens, Greece, ⁹LAIKO HOSPITAL, Athens, Greece
Background/Purpose: Giant cell arteritis (GCA) may affect temporal arteries (cranial-GCA) or may present as a systemic disease extended to the large vessels [Large Vessel Vasculitis…
Abstract Number: 0747 • ACR Convergence 2024
Clofutriben to Improve the Benefit-Risk Profile of Prednisolone in Patients with Polymyalgia Rheumatica
FRANK HARTMUT DR. BUTTGEREIT¹, Andrea Everding², Ioana Andreica³, Herbert Kellner⁴, Florian Schuch⁵, Tonya K Marmon⁶, Frank S Czerwiec⁷, Ketan Desai⁸ and David A Katz⁹, ¹Charité University Medicine Berlin, Berlin, Germany, ²Hamburger Rheuma Forschungszentrum II, Hamburg, Germany, ³Rheumazentrum Ruhrgebiet, Bochum, Germany, ⁴Schwerpunktpraxis f�r Rheumatologie und Gastroenterologie, Munich, Germany, ⁵PGRN, Erlangen, Germany, ⁶Marmon Biostatistics, Seattle, WA, ⁷Sparrow Pharmaceuticals, Portand, OR, ⁸IMC, Easton, PA, ⁹Sparrow Pharmaceuticals, Portland, OR
Background/Purpose: 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) differentially regulates intracellular glucocorticoid levels in the immune system and glucocorticoid toxicity target organs. Clofutriben is a potent HSD-1…
Abstract Number: 1629 • ACR Convergence 2024
Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica Has a Different Vascular Ultrasound Phenotype Than Giant Cell Arteritis
Sharon Cowley¹, Patricia Harkins², Colm Kirby³, Richard Conway⁴, David Kane⁵, Rositsa Karalilova⁶, Pierluigi Macchioni⁷, Christina Ponte⁸, Edoardo Conticini⁹, Alessandro Tomelleri¹⁰, Sara Monti¹¹, irene monjo¹², Zguro Batalov¹³, Giulia Klinowski⁷, Paolo Falsetti¹⁴, Corrado Campochiaro¹⁵, Alojzija Hocevar¹⁶ and Eugenio De Miguel¹⁷, ¹Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ²Trinity College Dublin, Dublin 8, Dublin, Ireland, ³Tallaght University Hospital, DUBLIN, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Clinic of Rheumatology, Medical University Plovdiv, Plovdiv, Bulgaria, Plovdiv, Bulgaria, ⁷Rheumatology Department, Ospedale S Maria Nuova, Reggio Emilia, Italy, Emilia, Italy, ⁸Rheumatology, Centro Hospitalar Universitario Lisboa Norte EPE, Lisboa, Portugal, Lisboa, Portugal, ⁹Università di Siena, Siena, Italy, ¹⁰Unit of Immunology, Allergology and Rare Diseases, IRCCS Ospedale San Raffaele, Milano, Italy, ¹¹IRCCS Istituto Auxologico Italiano, Milan, Italy, ¹²University Hospital La Paz, Madrid, Spain, ¹³Rheumatology, University Hospital Kaspela, Plovdiv, Bulgaria, Plovdiv, Bulgaria, ¹⁴Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Siena, Italy, Siena, Italy, ¹⁵IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ¹⁶University Medical Center Ljubljana, LJUBLJANA, Slovenia, ¹⁷Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Subclinical GCA in PMR has been estimated to affect 1 in 5 patients as assessed by vascular ultrasound [1, 2]. This study compared the ultrasound…
Abstract Number: 0748 • ACR Convergence 2024
Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica
Sebastian E. Sattui¹, Christian Dejaco², Kerri Ford³, Stefano Fiore⁴, Sebastian Unizony⁵, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹University of Pittsburgh, Pittsburgh, PA, ²Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Massachusetts General Hospital, Winchester, MA, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Treatment of polymyalgia rheumatica (PMR) is hindered by lack of glucocorticoid (GC)-sparing therapies with proven efficacy. A retrospective study showed a higher proportion of…
Abstract Number: 1637 • ACR Convergence 2024
Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease: Relation with Neoplasms and Role as a Paraneoplastic Syndrome
Pablo Muñoz Martínez¹, Claudia Fernandez Ruiz², Elena Grau García³, Samuel Leal Rodriguez³, José Ivorra-Cortés⁴, Carmen Riesco Barcena⁵, Anderson Huaylla Quispe⁵, Laura Mas Sánchez⁶, Daniel Ramos Castro⁵, Alba Torrat noves⁷, Iago Alcantara Alvarez⁸, Belén Villanueva Mañés⁸, Miguel Simeo Vinaixa⁸, Andrés Pérez Hurtado⁵ and Jose A Román-Ivorra⁹, ¹Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ²Escuela de Doctorado. UCV, Valencia, Comunidad Valenciana, Spain, ³HUP La Fe, Valencia, Spain, ⁴Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁵Rheumatology Department. HUP La Fe, Valencia, Spain, ⁶Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: The dysregulation of the immune system inherent in inflammatory diseases may contribute to the development of neoplasms. However, the relationship between the giant cell…
Abstract Number: 0755 • ACR Convergence 2024
Characteristics Associated with Long-Term Glucocorticoids Use in Patients with New Onset Polymyalgia Rheumatica
Anisha Dua¹, Andrea Rubbert-Roth², Kerri Ford³, Stefano Fiore⁴, Lita Araujo³, Timothy Beukelman⁵, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹Northwestern University Division of Rheumatology, Chicago, IL, ²Cantonal Hospital St Gallen, St Gallen, Switzerland, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Polymyalgia rheumatica (PMR), a common inflammatory rheumatic condition in people aged ≥50 years, is primarily treated with glucocorticoids (GC). Extended GC therapy can increase…
Abstract Number: 1697 • ACR Convergence 2024
Results of a One Year Randomized Double-Blind Placebo-Controlled Trial with Methotrexate 25mg Per Week for Recently Diagnosed PolyMyalgia Rheumatica
Thomas Bolhuis¹, Noortje Kooijman¹, Diane Marsman¹, Gijs Snijders², Alfons den Broeder³, Nathan den Broeder⁴ and Aatke Van der maas⁵, ¹Department of Rheumatology, Sint Maartenskliniek, Ubbergen, The Netherlands, Ubbergen, Netherlands, ²Department of Rheumatology, Gelre Ziekenhuizen, Apeldoorn, The Netherlands, Gelre, Netherlands, ³Sint Maartenskliniek, Ubbergen, Netherlands, ⁴Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ⁵St Maartenskliniek, Ubbergen, Netherlands
Background/Purpose: The most effective treatment for Polymyalgia rheumatica (PMR) are glucocorticoids (GC), but these are associated with toxicity. Three randomized controlled trials (RCTs) suggest methotrexate…
Abstract Number: 0756 • ACR Convergence 2024
Effectiveness and Safety of Tocilizumab in the Treatment of Polymyalgia Rheumatica: A Meta-Analysis
Ali Raza Khan¹, Nouman Shafique², Abdul Qadeer¹ and zaigham Shaukat¹, ¹Nishtar Medical University, Multan, Punjab, Pakistan, ²AdventHealth Orlando, Orlando, FL
Background/Purpose: Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) are different manifestations of the same disease process. GCA is a vasculitis that affects large and…
Abstract Number: 1698 • ACR Convergence 2024
Assessment of the Remission Maintenance After Tocilizumab Withdrawal in Polymyalgia Rheumatica Patients Receiving a 6-month Treatment
Baptiste Chevet¹, Aghiles Souki², nowak emmanuel², Guillermo CARVAJAL ALEGRIA³, Emmanuelle Dernis⁴, Christophe Richez⁵, Marie-Elise Truchetet⁶, DANIEL WENDLING⁷, ERIC TOUSSIROT⁸, aleth Perdriger⁹, Jacques-Eric Gottenberg¹⁰, Renaud FELTEN¹¹, Bruno Fautrel¹², laurent chiche¹³, Anne Walliser-Lohse¹⁴, Pascal Hilliquin¹⁵, Catherine Le Henaff¹⁶, Benjamin Dervieux¹⁷, Guillaume Direz¹⁸, Isabelle Valckenaere¹⁹, Divi Cornec²⁰, Dewi Guellec²¹, Thierry Marhadou²², Alain SARAUX²³ and Valerie Devauchelle²⁴, ¹University Hospital of Brest, Brest, France, ²Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, ³CHRU de Tours, Tours, France, ⁴CH LE MANS, LE MANS, Pays de la Loire, France, ⁵Université de Bordeaux, Bordeaux, France, ⁶Bordeaux University Hospital, Bordeaux, France, ⁷University Hospital, Besançon, France, ⁸university hospital of BESANCON, besancon, France, ⁹Rennes University, Rennes, France, ¹⁰Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹¹Hopitaux Universitaires de Strasbourg, STRASBOURG, France, ¹²INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ¹³hopital europeen, marseille, France, ¹⁴Hopital Nord Franche-Comté, BELFORT, France, ¹⁵Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France, ¹⁶Hopital de Morlaix, Morlaix, France, ¹⁷CH de Mulhouse - Competence center for autoimmune diseases, Internal Medicine, Mulhouse, France, ¹⁸Hôpital du Mans, Le Mans, France, ¹⁹CHU de Nancy, Nancy, France, ²⁰Service de Rhumatologie, CHU de Brest, Brest, France, ²¹CHU de Brest, Brest, France, ²²CHU Cavale Blanche, Brest, France, ²³CHU Brest, Brest, France, ²⁴UBO, Brest, France
Background/Purpose: The SEMAPHORE trial1 was a randomized controlled prospective study to assess the safety and efficacy (success defined by PMR-AS≤10 and GC≤5mg or GC decrease…
Abstract Number: 0762 • ACR Convergence 2024
Different Giant Cell Arteritis Phenotypes May Present Distinct Types of Ischemic Complications
Helena M Amar Muñoz¹, Juan Molina-Collada¹, Isabel Castrejon², irene monjo³, Elisa Fernández-Fernández:⁴, José María Álvaro-Gracia⁵ and Eugenio De Miguel⁶, ¹Hospital General Universitario Gregorio Marañón, MADRID, Spain, ²Hospital General Universitario Gregorio Marañon, Madrid, Spain, ³University Hospital La Paz, Madrid, Spain, ⁴La Paz University Hospital, Alcalá de Henares, Madrid, Spain, ⁵Hospital Gregorio Marañón, Madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: To determine if the subtype of vascular ultrasound (US) presentation is associated with different types of ischemic complications (IC) in giant cell arteritis (GCA).Methods: Retrospective…
Abstract Number: 1700 • ACR Convergence 2024
Comparative Effectiveness of Sarilumab vs. Methotrexate as a Glucocorticoid-Sparing Agent in Patients with Polymyalgia Rheumatica
Jeffrey Curtis¹, Fenglong Xie², Shanette Daigle³ and Sebastian E. Sattui⁴, ¹The University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³FASTER, Birmingham, AL, ⁴University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory condition that typically affects older individuals for whom long term glucocorticoid (GC) use may be undesirable. Moreover, the…
Abstract Number: 0768 • ACR Convergence 2024
Addressing Gaps in Polymyalgia Rheumatica: A Systematic Literature Review
Shelley Fritz¹, Angela Degrassi², Kelly Gavigan², Ruohan Hong³, Santiago Munoz Perez², Esteban Rivera⁴, Erik Stone⁵, Laura Stradford⁶, Ambika Vartak², Anne Sydor² and Shilpa Venkatachalam³, ¹Global Healthy Living Foundation, Kalaheo, HI, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Long Island City, NY, ⁵Global Healthy Living Foundation, Upper Nyack, ⁶Global Healthy Living Foundation, Nyack, NY
Background/Purpose: This systematic literature review on polymyalgia rheumatica (PMR) and PMR with giant cell arteritis (GCA) evaluates existing literature on disease burden, management, and treatment…
Abstract Number: 1704 • ACR Convergence 2024
Cluster Analysis of Peripheral Blood Mononuclear Cell Subpopulations Using Deep Immunophenotyping, Multiplex Serum Cytokines and Small Lipid Mediators at the Very Early Stages of Steroid Treatment in Polymyalgia Rheumatica and Giant Cell Arteritis
Dimitrios Anastasios Palamidas¹, Maria Papadaki², Nikolaos Paschalidis³, Eleftherios Pavlos⁴, Loukas chatzis¹, Ourania Argyropoulou⁵, Panagiota Palla⁵, Ioanna-Evdokia Galani⁶, Andreas Goules⁷, Evangelos Andreakos⁴ and Athanasios Tzioufas⁸, ¹Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ²Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Attiki, Greece, ³Mass Cytometry-CyTOF Laboratory, Center for Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece, Cholargos Athens, Greece, ⁴Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Athens, Greece, ⁵Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, ⁶Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Greece, ⁷GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, ⁸LAIKO HOSPITAL, Athens, Greece
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are autoimmune/autoinflammatory disorders affecting patients over 50 years and are characterized by an acute inflammatory response.…
Abstract Number: 0769 • ACR Convergence 2024
Baseline Evaluation of Diagnoses and Prescribing Patterns in Polymyalgia Rheumatica
Laura Stradford¹, Shilpa Venkatachalam², Kelly Gavigan³, Angela Degrassi³, Emily Holladay⁴, Fenglong xie⁵, Yujie Su⁶, Shanette Daigle⁷ and Jeffrey Curtis⁸, ¹Global Healthy Living Foundation, Nyack, NY, ²Global Healthy Living Foundation, New York, NY, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham; Illumination Health, Birmingham, AL, ⁶Illumination Health, Hoover, AL, ⁷FASTER, Birmingham, AL, ⁸University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Polymyalgia rheumatica (PMR) is a chronic inflammatory rheumatic condition that affects approximately 800,000 people in the U.S., occurring almost exclusively after age 50. Moreover,…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.